Across TCGA pan-cancer cohorts, RPL17P43 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated RPL17P43 data layer.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RPL17P43 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL17P43 expression acts as an unfavorable survival marker, although some lineages such as BRCA and CESC show a favorable association.
BRCA, CESC, and ACC are the cancer types where RPL17P43 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.